Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.75 |
| ▸ | THRB | P10828 | 4/20 | 0.75 |
| ▸ | TP53 | P04637 | 3/20 | 0.75 |
| ▸ | CETP | P11597 | 11/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249921 | 0.81 | MAPT (0.67) | MAPTTHRBTP53CETPSMN1; SMN2 | |
| SCHEMBL14096523 | 0.78 | MAPT (0.61) | MAPTTHRBTP53CETPSMN1; SMN2 | |
| SCHEMBL15177189 | 0.75 | MAPT (0.80) | MAPTTHRBTP53SMN1; SMN2RXFP1 | |
| SCHEMBL20768089 | 0.75 | CETP (1.00) | MAPTTP53CETP | |
| SCHEMBL12136722 | 0.75 | MAPT (0.81) | MAPTTHRBTP53CETPSMN1; SMN2 | |
| SCHEMBL9681997 | 0.74 | NPC1 (0.71) | MAPTTHRBTP53CETPSMN1; SMN2 | |
| SCHEMBL15745638 | 0.74 | NPC1 (0.66) | MAPTTHRBTP53CETPSMN1; SMN2 | |
| SCHEMBL8060238 | 0.72 | NPC1 (0.75) | MAPTTP53SMN1; SMN2HPGD | |
| SCHEMBL11446660 | 0.72 | NPC1 (0.64) | MAPTTHRBTP53CETPSMN1; SMN2 | |
| SCHEMBL1735101 | 0.72 | CEPT1 (0.70) | MAPTTHRBTP53CETPSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900219-B2 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1513534-A2 | COMPOUNDS FOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20030220356-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003084544-A2 | COMPOUNDS DOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220356-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | MAPT 4100/4885THRB 1762/4885TP53 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.